Stocks · News reference

Aurinia Pharmaceuticals shares are trading higher after the company announced it entered into a settlement agreement with Teva Pharmaceuticals.

Aug 20, 2026, 2:40 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 20, 2026, 1:30 PMVandana Singh
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug
Aurinia Pharmaceuticals shares rise after settling patent litigation with Teva, which can launch generic voclosporin no earlier than December 2036.
Read original at benzinga
AUPH TEVA
SEC EDGARAug 19, 2026, 8:11 PMSEC EDGAR
8-K filing — Aurinia Pharmaceuticals Inc. (AUPH)
Filed: 2026-08-19 AccNo: 0001600620-26-000066 Size: 177 KB Item 8.01: Other Events
Read original at edgar
AUPH
BenzingaAug 19, 2026, 8:07 PMBenzinga Newsdesk
Aurinia Settles Teva Patent Litigation, Protecting Voclosporin Exclusivity In U.S. Until December 2036 And Affirming Validity Of Key Patents Through 2037
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced that it and its subsidiary, Aurinia Pharma U.S., Inc., (collectively, "Aurinia") have entered into a settlement agreement with Teva Pharmaceuticals Inc.
Read original at benzinga
AUPH TEVA